牛牛AI助理已提取核心訊息
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of 15,789,474 shares of its common stock. The shares are listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The offering price per share is set at $9.50, aiming to raise approximately $150 million before expenses. Underwriters have been granted a 30-day option to purchase up to an additional 2,368,421 shares. The offering is expected to close on or about March 4, 2024. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are managing the offering. The proceeds are intended for funding the continued commercialization, development, and approval of Arcutis' multiple programs, including potential launches in atopic dermatitis and scalp psoriasis, and for general corporate purposes.
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of 15,789,474 shares of its common stock. The shares are listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The offering price per share is set at $9.50, aiming to raise approximately $150 million before expenses. Underwriters have been granted a 30-day option to purchase up to an additional 2,368,421 shares. The offering is expected to close on or about March 4, 2024. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are managing the offering. The proceeds are intended for funding the continued commercialization, development, and approval of Arcutis' multiple programs, including potential launches in atopic dermatitis and scalp psoriasis, and for general corporate purposes.
處於商業階段的生物製藥公司Arcutis Biotherapeutics宣佈發行15,789,474股普通股。這些股票在納斯達克全球精選市場上市，股票代碼爲 “ARQT”。每股發行價定爲9.50美元，目標是在支出前籌集約1.5億美元。承銷商已獲得30天的期權，可以額外購買最多2,368,421股股票。此次發行預計將於2024年3月4日左右結束。摩根士丹利、道明考恩、古根海姆證券、瑞穗和Needham & Company正在管理此次發行。所得款項旨在爲Arcutis多個項目的持續商業化、開發和批准提供資金，包括可能在特應性皮炎和頭皮牛皮癬領域推出，以及用於一般公司用途。
處於商業階段的生物製藥公司Arcutis Biotherapeutics宣佈發行15,789,474股普通股。這些股票在納斯達克全球精選市場上市，股票代碼爲 “ARQT”。每股發行價定爲9.50美元，目標是在支出前籌集約1.5億美元。承銷商已獲得30天的期權，可以額外購買最多2,368,421股股票。此次發行預計將於2024年3月4日左右結束。摩根士丹利、道明考恩、古根海姆證券、瑞穗和Needham & Company正在管理此次發行。所得款項旨在爲Arcutis多個項目的持續商業化、開發和批准提供資金，包括可能在特應性皮炎和頭皮牛皮癬領域推出，以及用於一般公司用途。
有用
沒用